Applied Therapeutics, Inc.
APLT

NASDAQ > Biotechnology
DCF:$1.15  |   P/E: -
$0.08(-8.98%)
Change
Rating:
Price: $0.8801 USD
Market Cap: $93.21M

...Loading APLT Peers...





Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

    37 Employees

    CEO : Dr. Riccardo Perfetti M.D., Ph.D.

    Address : 545 Fifth Avenue, New York,NY, US, - 10017,

Key ExcutivesDesignation
Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical Officer